Which has higher earnings & valuation, HIMS or GRAL?

Hims & Hers Health has higher revenue and earnings than GRAIL. Hims & Hers Health is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 3.40 $128.37M -$0.09 N/A GRAIL $147.17M 21.00 -$408.35M -$10.37 N/A

Is HIMS or GRAL more profitable?

Hims & Hers Health has a net margin of -0.56% compared to GRAIL's net margin of -253.22%. Hims & Hers Health's return on equity of 6.10% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets Hims & Hers Health -0.56% 6.10% 1.52% GRAIL -253.22% -16.42% -14.34%

Does the media refer more to HIMS or GRAL?

In the previous week, GRAIL had 25 more articles in the media than Hims & Hers Health. MarketBeat recorded 35 mentions for GRAIL and 10 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.83 beat GRAIL's score of 0.11 indicating that Hims & Hers Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, PACS or GRAL?

PACS Group has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PACS Group $5.29B 1.29 $191.54M $1.56 27.72 GRAIL $147.17M 21.00 -$408.35M -$10.37 N/A

Is PACS or GRAL more profitable?

PACS Group has a net margin of 4.49% compared to GRAIL's net margin of -253.22%. PACS Group's return on equity of 26.47% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets PACS Group 4.49% 26.47% 4.36% GRAIL -253.22% -16.42% -14.34%

Does the media refer more to PACS or GRAL?

In the previous week, GRAIL had 12 more articles in the media than PACS Group. MarketBeat recorded 35 mentions for GRAIL and 23 mentions for PACS Group. GRAIL's average media sentiment score of 0.11 beat PACS Group's score of 0.01 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 7 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GRAL or BLLN?

Billiontoone has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 21.00 -$408.35M -$10.37 N/A Billiontoone $305.11M 19.11 $7.45M $0.55 230.49

Is GRAL or BLLN more profitable?

Billiontoone has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Billiontoone's return on equity of 0.00% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Billiontoone N/A N/A N/A

Does the media refer more to GRAL or BLLN?

In the previous week, GRAIL had 28 more articles in the media than Billiontoone. MarketBeat recorded 35 mentions for GRAIL and 7 mentions for Billiontoone. GRAIL's average media sentiment score of 0.11 beat Billiontoone's score of -0.05 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Billiontoone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GRAL or CAI?

Caris Life Sciences has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 21.00 -$408.35M -$10.37 N/A Caris Life Sciences $812.03M 5.91 -$68.09M -$7.61 N/A

Is GRAL or CAI more profitable?

Caris Life Sciences has a net margin of 3.75% compared to GRAIL's net margin of -253.22%. Caris Life Sciences' return on equity of 98.28% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Caris Life Sciences 3.75% 98.28% 48.87%

Does the media refer more to GRAL or CAI?

In the previous week, GRAIL had 30 more articles in the media than Caris Life Sciences. MarketBeat recorded 35 mentions for GRAIL and 5 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.69 beat GRAIL's score of 0.11 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, GRAL or SHC?

Sotera Health has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 21.00 -$408.35M -$10.37 N/A Sotera Health $1.16B 4.51 $77.94M $0.41 44.93

Is GRAL or SHC more profitable?

Sotera Health has a net margin of 9.91% compared to GRAIL's net margin of -253.22%. Sotera Health's return on equity of 39.73% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Sotera Health 9.91% 39.73% 7.05%

Does the media prefer GRAL or SHC?

In the previous week, GRAIL had 33 more articles in the media than Sotera Health. MarketBeat recorded 35 mentions for GRAIL and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.73 beat GRAIL's score of 0.11 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sotera Health 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

GRAIL (GRAL) Competitors

$72.00 -3.79 (-5.00%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$72.88 +0.88 (+1.23%)

As of 07/10/2026 07:40 PM Eastern

Compare

GRAL vs. HIMS, PACS, BLLN, CAI, and SHC

Should you buy GRAIL stock or one of its competitors? MarketBeat compares GRAIL with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GRAIL include Hims & Hers Health (HIMS), PACS Group (PACS), Billiontoone (BLLN), Caris Life Sciences (CAI), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does GRAIL compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and GRAIL (NASDAQ:GRAL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, GRAIL had 25 more articles in the media than Hims & Hers Health. MarketBeat recorded 35 mentions for GRAIL and 10 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.83 beat GRAIL's score of 0.11 indicating that Hims & Hers Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hims & Hers Health has higher revenue and earnings than GRAIL. Hims & Hers Health is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	3.40	$128.37M	-$0.09	N/A
GRAIL	$147.17M	21.00	-$408.35M	-$10.37	N/A

Hims & Hers Health presently has a consensus target price of $30.70, indicating a potential downside of 10.88%. GRAIL has a consensus target price of $67.00, indicating a potential downside of 6.94%. Given GRAIL's stronger consensus rating and higher probable upside, analysts clearly believe GRAIL is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Hims & Hers Health has a net margin of -0.56% compared to GRAIL's net margin of -253.22%. Hims & Hers Health's return on equity of 6.10% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
GRAIL	-253.22%	-16.42%	-14.34%

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Hims & Hers Health has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.22, suggesting that its share price is 222% more volatile than the broader market.

Summary

Hims & Hers Health beats GRAIL on 9 of the 15 factors compared between the two stocks.

How does GRAIL compare to PACS Group?

PACS Group (NYSE:PACS) and GRAIL (NASDAQ:GRAL) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

In the previous week, GRAIL had 12 more articles in the media than PACS Group. MarketBeat recorded 35 mentions for GRAIL and 23 mentions for PACS Group. GRAIL's average media sentiment score of 0.11 beat PACS Group's score of 0.01 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	7 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PACS Group has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.29	$191.54M	$1.56	27.72
GRAIL	$147.17M	21.00	-$408.35M	-$10.37	N/A

PACS Group presently has a consensus price target of $50.60, indicating a potential upside of 17.02%. GRAIL has a consensus price target of $67.00, indicating a potential downside of 6.94%. Given PACS Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe PACS Group is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

PACS Group has a net margin of 4.49% compared to GRAIL's net margin of -253.22%. PACS Group's return on equity of 26.47% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
GRAIL	-253.22%	-16.42%	-14.34%

PACS Group has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.22, suggesting that its stock price is 222% more volatile than the broader market.

Summary

PACS Group beats GRAIL on 10 of the 14 factors compared between the two stocks.

How does GRAIL compare to Billiontoone?

GRAIL (NASDAQ:GRAL) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Billiontoone has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Billiontoone's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Billiontoone	N/A	N/A	N/A

GRAIL presently has a consensus price target of $67.00, suggesting a potential downside of 6.94%. Billiontoone has a consensus price target of $126.00, suggesting a potential downside of 0.61%. Given Billiontoone's stronger consensus rating and higher possible upside, analysts clearly believe Billiontoone is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Billiontoone has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	21.00	-$408.35M	-$10.37	N/A
Billiontoone	$305.11M	19.11	$7.45M	$0.55	230.49

In the previous week, GRAIL had 28 more articles in the media than Billiontoone. MarketBeat recorded 35 mentions for GRAIL and 7 mentions for Billiontoone. GRAIL's average media sentiment score of 0.11 beat Billiontoone's score of -0.05 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Billiontoone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Billiontoone beats GRAIL on 10 of the 13 factors compared between the two stocks.

How does GRAIL compare to Caris Life Sciences?

GRAIL (NASDAQ:GRAL) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Caris Life Sciences has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	21.00	-$408.35M	-$10.37	N/A
Caris Life Sciences	$812.03M	5.91	-$68.09M	-$7.61	N/A

Caris Life Sciences has a net margin of 3.75% compared to GRAIL's net margin of -253.22%. Caris Life Sciences' return on equity of 98.28% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Caris Life Sciences	3.75%	98.28%	48.87%

GRAIL currently has a consensus target price of $67.00, suggesting a potential downside of 6.94%. Caris Life Sciences has a consensus target price of $26.11, suggesting a potential upside of 53.69%. Given Caris Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, GRAIL had 30 more articles in the media than Caris Life Sciences. MarketBeat recorded 35 mentions for GRAIL and 5 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.69 beat GRAIL's score of 0.11 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Caris Life Sciences beats GRAIL on 11 of the 13 factors compared between the two stocks.

How does GRAIL compare to Sotera Health?

GRAIL (NASDAQ:GRAL) and Sotera Health (NASDAQ:SHC) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

GRAIL has a beta of 3.22, indicating that its stock price is 222% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

GRAIL currently has a consensus price target of $67.00, indicating a potential downside of 6.94%. Sotera Health has a consensus price target of $20.25, indicating a potential upside of 9.93%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts clearly believe Sotera Health is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Sotera Health has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	21.00	-$408.35M	-$10.37	N/A
Sotera Health	$1.16B	4.51	$77.94M	$0.41	44.93

Sotera Health has a net margin of 9.91% compared to GRAIL's net margin of -253.22%. Sotera Health's return on equity of 39.73% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Sotera Health	9.91%	39.73%	7.05%

91.0% of Sotera Health shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 15.4% of Sotera Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, GRAIL had 33 more articles in the media than Sotera Health. MarketBeat recorded 35 mentions for GRAIL and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.73 beat GRAIL's score of 0.11 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sotera Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sotera Health beats GRAIL on 13 of the 16 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAL vs. The Competition

Export

Metric	GRAIL	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.25B	$3.76B	$7.14B	$12.64B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-6.94	21.83	27.42	24.58
Price / Sales	21.00	323.85	593.42	121.62
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	1.09	8.41	10.88	6.38
Net Income	-$408.35M	$23.85M	$3.59B	$331.87M
7 Day Performance	4.18%	-0.75%	-0.26%	0.37%
1 Month Performance	19.68%	8.81%	4.52%	0.53%
1 Year Performance	76.77%	53.66%	29.17%	21.96%

GRAIL Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAL GRAIL	0.9352 of 5 stars	$72.00 -5.0%	$67.00 -6.9%	+65.9%	$3.25B	$147.17M	N/A	1,360	Trending News
HIMS Hims & Hers Health	2.7693 of 5 stars	$33.36 -1.7%	$29.37 -12.0%	-31.4%	$7.86B	$2.37B	N/A	2,442	Analyst Forecast Insider Trade
PACS PACS Group	3.2973 of 5 stars	$39.94 -4.7%	$48.00 +20.2%	+238.1%	$6.63B	$5.29B	25.60	47,455	Analyst Forecast Insider Trade
BLLN Billiontoone	1.7635 of 5 stars	$120.40 +1.9%	$126.00 +4.7%	N/A	$5.44B	$305.11M	218.91	620	Insider Trade
CAI Caris Life Sciences	4.3067 of 5 stars	$18.32 -1.0%	$27.56 +50.4%	N/A	$5.23B	$812.03M	N/A	1,846	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAL) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRAIL (GRAL) Competitors

GRAL vs. HIMS, PACS, BLLN, CAI, and SHC

How does GRAIL compare to Hims & Hers Health?

Summary

How does GRAIL compare to PACS Group?

Summary

How does GRAIL compare to Billiontoone?

Summary

How does GRAIL compare to Caris Life Sciences?

Summary

How does GRAIL compare to Sotera Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRAIL (GRAL) Competitors

GRAL vs. HIMS, PACS, BLLN, CAI, and SHC

How does GRAIL compare to Hims & Hers Health?

Does the media refer more to HIMS or GRAL?

Which has higher earnings & valuation, HIMS or GRAL?

Do analysts rate HIMS or GRAL?

Is HIMS or GRAL more profitable?

Do institutionals & insiders believe in HIMS or GRAL?

Which has more risk and volatility, HIMS or GRAL?

Summary

How does GRAIL compare to PACS Group?

Does the media refer more to PACS or GRAL?

Which has stronger earnings & valuation, PACS or GRAL?

Do analysts prefer PACS or GRAL?

Is PACS or GRAL more profitable?

Which has more volatility & risk, PACS or GRAL?

Summary

How does GRAIL compare to Billiontoone?

Is GRAL or BLLN more profitable?

Do analysts recommend GRAL or BLLN?

Which has better valuation & earnings, GRAL or BLLN?

Does the media refer more to GRAL or BLLN?

Summary

How does GRAIL compare to Caris Life Sciences?

Which has higher valuation and earnings, GRAL or CAI?

Is GRAL or CAI more profitable?

Do analysts prefer GRAL or CAI?

Does the media refer more to GRAL or CAI?

Summary

How does GRAIL compare to Sotera Health?

Which has more risk & volatility, GRAL or SHC?

Do analysts rate GRAL or SHC?

Which has stronger earnings and valuation, GRAL or SHC?

Is GRAL or SHC more profitable?

Do insiders & institutionals have more ownership in GRAL or SHC?

Does the media prefer GRAL or SHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools